Mylan gets DCGI nod for remdesivir in India, to launch at Rs 4,800 per vial – ET HealthWorld

NEW DELHI: Pharmaceutical major Mylan NV on Monday said it has received approval from Indian drugs regulator DCGI to manufacture and market its remdesivir for restricted emergency use in the country for the treatment of COVID-19. The drug will be priced at Rs 4,800 per 100 mg vial and would be available to the patients […]